p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy

Leuk Res. 2014 Feb;38(2):243-50. doi: 10.1016/j.leukres.2013.11.012. Epub 2013 Nov 24.

Abstract

Flowcytometry analysis was carried out to evaluate the expression of the p-Stat3 in 50 CML patients and 20 age-matched healthy controls. p-Stat3 expression was increased in advanced stages of CML. Imatinib treatment was found to suppress the expression of p-Stat3 in bone marrow cells. The level of p-Stat3 was found to be higher in resistant cases than in responsive cases, which suggest the beneficial use of p-Stat3 as an indicator to follow the clinical course and the treatment response.

Keywords: Chronic myeloid leukemia; Imatinib; Stat3; bcr-abl.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Case-Control Studies
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Gene Expression Regulation, Leukemic
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Male
  • Middle Aged
  • Phosphorylation
  • Piperazines / therapeutic use*
  • Protein Kinases / metabolism*
  • Pyrimidines / therapeutic use*
  • STAT3 Transcription Factor / metabolism*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Imatinib Mesylate
  • Protein Kinases
  • Fusion Proteins, bcr-abl